The role of plasminogen in angiogenesis in vivo

Journal of Thrombosis and Haemostasis

Volumn 1, Issue 8, 2003, Pages 1683-1687

  Oh, C W ^a   Hoover Plow, J ^b   Plow, E F ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b Seoul National University College of Medicine   (South Korea)

Author keywords

In vivo angiogenesis; Mouse corneal model; Plasminogen deficient mice; Urokinase; Urokinase receptor

Indexed keywords

CELL SURFACE RECEPTOR; FIBROBLAST GROWTH FACTOR 2; PLASMINOGEN; PLASMINOGEN ACTIVATOR, UROKINASE RECEPTORS; UROKINASE;

ANGIOGENESIS; ANIMAL; ARTICLE; C57BL MOUSE; CORNEA; EXTRACELLULAR MATRIX; FEMALE; GENOTYPE; HUMAN; MALE; METABOLISM; MOUSE; PHYSIOLOGY; TIME; TRANSGENIC MOUSE;

ANIMALS; CORNEA; EXTRACELLULAR MATRIX; FEMALE; FIBROBLAST GROWTH FACTOR 2; GENOTYPE; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOVASCULARIZATION, PHYSIOLOGIC; PLASMINOGEN; RECEPTORS, CELL SURFACE; TIME FACTORS; URINARY PLASMINOGEN ACTIVATOR;

EID: 2142755773     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1046/j.1538-7836.2003.00182.x     Document Type: Article

References (43)

1. Folkman J. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N EnglJ Med 1995; 333: 1757-63.
2. Pepper MS. Manipulating angiogenesis: From basic science to the bedside. Arterioscler Thromb Vase Biol 1997; 17: 605-19.
3. Carmeliet P, Collen D. Vascular development and disorders: Molecular anlaysis and pathogenic insights. Kidney Int 1998; 53: 1519-49.
4. Sledge GW Jr, Miller KD. Angiogenesis and antiangiogenic therapy. Curr Probl Cancer 2002; 26: 1-60.
5. Tosetti F, Ferrari N, De Flora S, Albini A. Angioprevention: angiogenesis is a common and key target for cancer chemopreventive agents. FASEB J 2002; 16: 2-14.
6. Libby P, Schonbeck U. Drilling for oxygen: angiogenesis involves proteolysis of the extracellular matrix. Circ Res 2001; 89: 195-7.
7. Pepper MS. Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. Arterioscler Thromb Vase Biol 2001; 21: 1104-17.
8. Plow EF, Ploplis VA, Carmeliet P, Collen D. Plasminogen and cell migration in vivo. Fibrinolysis Proteolysis 1999; 13: 49-53.
9. Bastaki M, Nelli EE, Dell'Era P, Rusnati M, Molinari-Tosatti MP, Parolini S, Auerbach R, Ruco LP, Possati L, Presta M. Basic fibroblast growth factor-induced angiogenic phenotype in mouse endothelium. A study of aortic and microvascular endothelial cell lines. Arterioscler Thromb Vase Biol 1997; 17: 454-64.
10. Brodsky S, Chen J, Lee A, Akassoglou K, Norman J, Goligorsky MS. Plasmin-dependent and -independent effects of plasminogen activators and inhibitor-1 on ex vivo angiogenesis. Am J Physiol Heart Circ Physiol 2001; 281: H1784-H1792.
11. Devy L, Blacher S, Grignet-Debrus C, Bajou K, Masson R, Gerard RD, Giles A, Carmeliet G, Carmeliet P, Declerck P, Noel A, Foidart JM. The pro- or antioangiogenic effect of plasminogen activator inhibitor 1 is dose dependent. FASEB J 2002; 16: 147-54.
12. Gutierrez LS, Schulman A, Brito-Robinson T, Noria F, Ploplis VA, Castellino FJ. Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1. Cancer Res 2000; 60: 5839-47.
13. Ren CJ, Ueda F, Roses DF, Harris MN, Mignatti P, Rifkin DB, Shapiro RL. Irsogladine maleate inhibits angiogenesis in wild-type and plasminogen activator-deficient mice. J Surg Res 1998; 77: 126-31.
14. Kenyon BM, Voest EE, Chen CC, Flynn E, Folkman J, D'Amato RJ. A model of angiogenesis in the mouse cornea. Invest Ophthalmol Vis Sci 1996; 37: 1625-32.
15. Kato T, Kure T, Chang JH, Gabison EE, Itoh T, Itohara S, Azar DT. Diminished corneal angiogenesis in gelatinase A-deficient mice. FEBS Lett 2001; 508: 187-90.
16. Smith RS, Hawes NL, Kuhlmann SD, Heckenlively JR, Chang B, Roderick TH, Sundberg JP. Cornl: a mouse model for corneal surface disease and neovascularization. Invest Ophthalmol Vis Sci 1996; 37: 397-404.
17. Kintner RL, Brandt CR. The effect of viral inoculum level and host age on disease incidence, disease severity, and mortality in a murine model of ocular HSV-1 infection. Curr Eye Res 1995; 14: 145-52.
18. Cao Y, Linden P, Farnebo J, Cao R, Eriksson A, Kumar V, Qi JH, Claesson-Welsh L, Alitalo K. Vascular endothelial growth factor C induces angiogenesis in vivo. Proc Natl Acad Sci USA 1998; 95: 14389-94.
19. Ploplis VA, Carmeliet P, Vazirzadeh S, Van Vlaenderen I, Moons L, Plow EF, Collen D. Effects of disruption of the plasminogen gene in mice on thrombosis, growth and health. Circulation 1995; 92: 2585-93.
20. Hoover-Plow J, Wang N, Ploplis V Growth and behavioral development in plasminogen gene-targeted mice. Growth Dev Aging 1999; 63: 13-32.
21. Hoover-Plow J, Ellis J, Yuen L. In vivo plasminogen deficiency reduces fat accumulation. Thromb Haemost 2002; 87: 1011-9.
22. Hoover-Plow J, Skomorovska-Prokvolit O, Welsh S. Selective behaviors altered in plasminogen-deficient mice are reconstituted with intracerebroventricular injection of plasminogen. Brain Res 2001; 898: 256-64.
23. Carmeliet P, Moons L, Ploplis V, Plow E, Collen D. Impaired arterial neointima formation in mice with disruption of the plasminogen gene. J Clin Invest 1997; 99: 200-8.
24. Lijnen HR, Van Hoef B, Lupu F, Moons L, Carmeliet P, Collen D. Function of the plasminogen/plasmin and matrix metalloproteinase systems after vascular injury in mice with targeted inactivation of fibrinolytic system genes. Arterioscler Thromb Vase Biol 1998; 18: 1035-45.
25. Ny A, Leonardsson G, Hägglund AC, Hägglöf P, Ploplis VA, Carmeliet P, Ny T. Ovulation in plasminogen-deficient mice. Endocrinology 1999; 140: 5030-5.
26. Rohan RM, Fernandez A, Udagawa T, Yuan J, D'Amato RJ. Genetic heterogeneity of angiogenesis in mice. FASEB J 2000; 14: 871-6.
27. Reed MJ, Corsa A, Pendergrass W, Penn P, Sage EH, Abrass IB. Neovascularization in aged mice, delayed angiogenesis is coincident with decreased levels of transforming growth factor betal and type I collagen. Am J Pathol 1998; 152: 113-23.
28. Morales DE, McGowan KA, Grant DS, Maheshwari S, Bhartiya D, Cid MC, Kleinman HK, Schnaper HW. Estrogen promotes angiogenic activity in human umbilical vein endothelial cells in vitro and in a murine model. Circulation 1995; 91: 755-63.
29. Stewart RJ, Panigrahy D, Flynn E, Folkman J. Vascular endothelial growth factor expression and tumor angiogenesis are regulated by androgens in hormone responsive human prostate carcinoma: evidence for androgen dependent destabilization of vascular endothelial growth factor transcripts. J Urol 2001; 165: 688-93.
30. Bonnefoy A, Legrand C. Proteolysis of subendothelial adhesive glyco-proteins (fibronectin, thrombospondin, and von Willebrand factor) by plasmin, leukocyte cathepsin G, and elastase. Thromb Res 2000; 98: 323-32.
31. Saksela O, Rifkin DB. Release of basic fibroblast growth factor-heparan sulfate complexes from endothelial cells by plasminogen activator-mediated proteolytic activity. J Cell Biol 1990; 110: 767-75.
32. Seghezzi G, Patel S, Ren CJ, Gualandris A, Pintucci G, Robbins ES, Shapiro RL, Galloway AC, Rifkin DB, Mignatti P. Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: an autocrine mechanism contributing to angiogenesis. J Cell Biol 1998; 141: 1659-73.
33. George SJ, Johnson JL, Smith MA, Jackson CL. Plasmin-mediated fibroblast growth factor-2 mobilisation supports smooth muscle cell proliferation in human saphenous vein. J Vase Res 2001; 38: 492-501.
34. Ribatti D, Leali D, Vacca A, Giuliani R, Gualandris A, Roncali L, Nolli ML, Presta M. In vivo angiogenic activity of urokinase: role of endogenous fibroblast growth factor-2. J Cell Sci 1999; 112: 4213-21.
35. Twining SS, Wilson PM, Ngamkitidechakul C. Extrahepatic synthesis of plasminogen in the human cornea is up-regulated by interleukins-la and -lb. Biochem J 1999; 339: 705-12.
36. Cavallaro U, Tenan M, Castelli V, Perilli A, Maggiano N, Van Meir EG, Montesano R, Soria MR, Pepper MS. Response of bovine endothelial cells to FGF-2 and VEGF is dependent on their site of origin: relevance to the regulation of angiogenesis. J Cell Biochem 2001; 82: 619-33.
37. Bugge TH, Suh TT, Flick MJ, Daugherty CC, Romer J, Solberg H, Ellis V, Dano K, Degen JL. The receptor for urokinase-type plasminogen activator is not essential for mouse development or fertility. J Biol Chem 1995; 270: 16886-94.
38. Bugge TH, Flick MJ, Danton MJS, Daugherty CC, Romer J, Dano K, Carmeliet P, Collen D, Degen JL. Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator. Proc Natl Acad Sci USA 1996; 93: 5899-904.
39. Dewerchin M, Nuffelen AV, Wallays G, Bouche A, Moons L, Carmeliet P. Generation and characterization of urokinase receptor-deficient mice. J Clin Invest 1996; 97: 870-8.
40. Stefansson S, Petitclerc E, Wong MKK, McMahon GA, Brooks PC. Lawrence DA. Inhibition of angiogenesis in vivo by plasminogen activator inhibitor-1. J Biol Chem 2001; 276: 8135-41.
41. Bajou K, Masson V, Gerard RD, Schmitt PM, Albert V, Praus M, Lund LR, Frandsen TL, Brunner N, Dano K, Fusenig NE, Weidle U, Carmeliet G, Loskutoff D, Collen D, Carmeliet P, Foidart JM, Noel A. The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies. J Cell Biol 2001; 152: 777-84.
42. Lambert V, Munaut C, Noel A, Frankenne F, Bajou K, Gerard R, Carmeliet P, Defresne MP, Foidart JM, Rakic JM. Influence of plas-minogen activator inhibitor type 1 on choroidal neovascularization. FASEB J 2001; 15: 1021-7.
43. McMahon GA, Petitclerc E, Stefansson S, Smith E, Wong MK, Westrick RJ, Ginsburg D, Brooks PC. Lawrence DA. Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis. J Biol Chem 2001; 276: 33964-8.